These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34742340)

  • 1. Meeting report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017.
    Miner MD; Bekker LG; Kredo T; Bhagwandin N; Corey L; Gray GE
    Trials; 2021 Nov; 22(1):778. PubMed ID: 34742340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial.
    Beesham I; Heffron R; Evans S; Baeten JM; Smit J; Beksinska M; Mansoor LE
    AIDS Behav; 2021 Apr; 25(4):1112-1119. PubMed ID: 33106996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.
    Donnell D; Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Rees H; Baeten JM;
    Lancet HIV; 2021 Aug; 8(8):e495-e501. PubMed ID: 34126052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key stakeholders' perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa.
    Beesham I; Milford C; Joseph Davey DL; Smit J; Mansoor LE; Beksinska M
    Afr J AIDS Res; 2023 Apr; 22(1):18-26. PubMed ID: 36951406
    [No Abstract]   [Full Text] [Related]  

  • 5. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
    Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Donnell D; Baeten JM;
    J Int AIDS Soc; 2020 May; 23(5):e25491. PubMed ID: 32396700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe.
    Friedland BA; Mgodi NM; Palanee-Phillips T; Mathur S; Plagianos MG; Bruce IV; Lansiaux M; Murombedzi C; Musara P; Dandadzi A; Reddy K; Ndlovu N; Zulu SK; Shale LR; Zieman B; Haddad LB
    BMJ Open; 2024 Mar; 14(3):e075381. PubMed ID: 38479746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.
    Beesham I; Joseph Davey DL; Beksinska M; Bosman S; Smit J; Mansoor LE
    AIDS Behav; 2022 Aug; 26(8):2623-2631. PubMed ID: 35122575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policy considerations for scaling up access to HIV pre-exposure prophylaxis for adolescent girls and young women: Examples from Kenya, South Africa, and Uganda.
    Lane J; Brezak A; Patel P; Verani AR; Benech I; Katz A
    Int J Health Plann Manage; 2021 Sep; 36(5):1789-1808. PubMed ID: 34159630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
    Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
    Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa.
    Beesham I; Milford C; Smit J; Joseph Davey DL; Baeten JM; Heffron R; Beksinska M; Mansoor LE
    BMC Public Health; 2023 Jun; 23(1):1210. PubMed ID: 37349816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PrEP implementation research in Africa: what is new?
    Cowan FM; Delany-Moretlwe S; Sanders EJ; Mugo NR; Guedou FA; Alary M; Behanzin L; Mugurungi O; Bekker LG
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21101. PubMed ID: 27760680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.
    Hankins C; Macklin R; Warren M
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19973. PubMed ID: 26198343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
    Nicol E; Ramraj T; Hlongwa M; Basera W; Jama N; Lombard C; McClinton-Appollis T; Govindasamy D; Pass D; Funani N; Aheron S; Paredes-Vincent A; Drummond J; Cheyip M; Dladla S; Bedford J; Mathews C
    PLoS One; 2022; 17(3):e0264808. PubMed ID: 35298487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
    Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
    PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?
    Stankevitz K; Schwartz K; Hoke T; Li Y; Lanham M; Mahaka I; Mullick S
    PLoS One; 2019; 14(6):e0218556. PubMed ID: 31226165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
    Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
    Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
    Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
    Beesham I; Mansoor LE; Joseph Davey DL; Palanee-Phillips T; Smit J; Ahmed K; Selepe P; Louw C; Singata-Madliki M; Kotze P; Heffron R; Parikh UM; Wiesner L; Rees H; Baeten JM; Beksinska M
    J Acquir Immune Defic Syndr; 2022 Sep; 91(1):26-30. PubMed ID: 35972853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.